Analysis of domestic listing and purchasing channels of Daprodustat

Daprodustat (Daprodustat), as an oral HIF-PHI anti-anemia drug, has gradually entered the clinical application stage in the international market in recent years, but its launch in the Chinese market is relatively lagging behind. At present, the original drug of daprostat has not been approved for marketing in China, so there are still certain limitations in clinical application and purchase channels in China. According to public information, the drug has not yet been included in the national medical insurance catalog, so its price information is temporarily unclear. If patients need to use it, they will often seek to obtain it through cross-border channels, but such methods need to pay attention to drug quality and compliance issues.

Overseas, daprostat has been launched by large pharmaceutical companies and has been launched in Japan, Europe and other places. Common specifications include1 mg 30 tablets, 2 mg 30 tablets, etc., which are suitable for long-term oral treatment of patients with chronic kidney disease and anemia. With the expansion of the scope of use, some countries have already launched the first batch of generic drugs of daprostat. For example, the generic version produced by Lucius Pharmaceuticals in Laos with a specification of 1mg*100 tablets has attracted attention in some countries because of its lower price. Although the ingredients of generic drugs are basically the same as those of original drugs, there may still be differences in quality control and production standards. Patients should pay attention to formal channels when choosing.

For domestic patients, if there is a clinical need for daprexostat, there are currently two main ways to obtain it: one is to use the original drug by participating in clinical trials, which is the most formal and safe way; the other is to order through overseas channels or international pharmacies, but this channel has policy and safety risks. Especially when it comes to long-term medication for chronic diseases, the source and authenticity of cross-border drugs are issues that cannot be ignored.

As China's treatment demand in the field of nephrology continues to increase, daprostat is expected to accelerate the review and approval process in the country in the future. If it is successfully marketed and entered into medical insurance, it will significantly reduce the financial burden on patients and promote the transformation of the treatment model of anemia treatment from injection preparations to oral small molecule drugs.

Reference materials:https://en.wikipedia.org/wiki/Daprodustat